<SEC-DOCUMENT>0001144204-15-068284.txt : 20160120
<SEC-HEADER>0001144204-15-068284.hdr.sgml : 20160120
<ACCEPTANCE-DATETIME>20151127131648
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001144204-15-068284
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20151127

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				650643773
		STATE OF INCORPORATION:			FL
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			20100
		BUSINESS PHONE:		972-4-988-9488

	MAIL ADDRESS:	
		STREET 1:		2 SNUNIT ST
		STREET 2:		SCIENCE PARK, POB 455
		CITY:			CARMIEL
		STATE:			L3
		ZIP:			20100

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><IMG SRC="image_001.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">November 27, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Suzanne Hayes</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Assistant Director</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Office of Healthcare and Insurance</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities and Exchange Commission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Division of Corporate Finance</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mail Stop 4720</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">100 F Street, N.E.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Washington, D.C. &nbsp;20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in; text-align: left">Re:</TD><TD STYLE="text-align: justify"><U>Protalix BioTherapeutics, Inc.</U></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><U>Registration Statement on Form S-3</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><U>Filed November 13, 2015</U><BR>
<U>File No. 333-208004</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Ms. Hayes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Reference is made to Amendment No. 1 to the Registration Statement
on Form S-3 (File No. 333-208004) (the &ldquo;Registration Statement&rdquo;) filed by Protalix BioTherapeutics, Inc. (the &ldquo;Company&rdquo;)
on November 27, 2015. &nbsp;The initial Registration Statement was filed with the Commission on November 13, 2015. The amended
Registration Statement was filed with the Securities and Exchange Commission (&ldquo;Commission&rdquo;) in response to the comments
of the staff (the &ldquo;Staff&rdquo;) that were contained in your letter dated November 19, 2015 (the &ldquo;Comment Letter&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Responses to Comment Letter</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following are the Company&rsquo;s responses to the issues
and questions raised by the Staff in the Comment Letter. &nbsp;We have noted the Staff&rsquo;s comments below in bold face type
and the responses in regular type.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>General</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>1.</B>&#9;<B>We note you have a confidential treatment request
that is outstanding. &nbsp;The request will need to be granted prior to the effectiveness of this registration statement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We understand that our outstanding confidential treatment request
must be granted before the Registration Statement can be declared effective. We will not request effectiveness until the Staff
has granted the confidential treatment request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Exhibit Index, page II-9 </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>2. &#9;We note that you intend to file your forms of indenture
by amendment or with current reports on Form 8-K. Please be advised that these documents must be filed as exhibits to your registration
statement prior to effectiveness, as this is when the indentures will be qualified pursuant to the Trust Indenture Act of 1939.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 8pt">2 Snunit Street,
Science Park P.O.B. 455, Carmiel 20100, Israel</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 8pt">Tel: 972-4-988-9488
| Fax: 972-4-988-9489 | Web: www.protalix.com&#9;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Exhibit Index, page II-9 </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>2. &#9;We note that you intend to file your forms of indenture
by amendment or with current reports on Form 8-K. Please be advised that these documents must be filed as exhibits to your registration
statement prior to effectiveness, as this is when the indentures will be qualified pursuant to the Trust Indenture Act of 1939.
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">In response to the Staff&rsquo;s comment, the Company has filed
forms of indenture in Amendment No. 1 described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9;*&#9;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company hereby acknowledges that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">should the Commission or the Staff, acting
pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with
respect to the filing; </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: left; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">the action of the Commission or the Staff,
acting pursuant to delegated authority, in declaring the filing effective, does not relieve the company from its full responsibility
for the adequacy and accuracy of the disclosure in the filing; and </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: left; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 28.35pt"></TD><TD STYLE="width: 28.35pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">the Company may not assert Staff comments
and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal
securities laws of the United States.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company would be grateful if the Staff would provide any
comments to the amended Registration Statement at its earliest convenience so that the Company may provide any additional responses
required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We thank you in advance for your time and attention to these
amendments, as well as to our comments. Should you wish to discuss the enclosed materials at any time, please do not hesitate to
contact me at +972 (4) 902-8100 or YossiM@protalix.com or the Company&rsquo;s counsel, James R. Tanenbaum of Morrison &amp; Foerster
LLP at +1 (212) 468-8163 or jtanenbaum@mofo.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sincerely,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Yossi Maimon<BR>
Yossi Maimon<BR>
Vice President and Chief Financial Officer<BR>
Protalix BioTherapeutics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">cc:</TD><TD STYLE="text-align: justify">Moshe Manor</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Protalix BioTherapeutics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt; margin-left: 0.5in">James R. Tanenbaum<BR>
Morrison &amp; Foerster LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection Last; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  W *4# 2(  A$! Q$!_\0
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A<J,C\:5T612KJ&4]0PR#110 H 50J@  8 ':BBB@#__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
